Ahmed, Atique, PhD



Ahmed, Atique, PhD


Assistant Professor



Office Phone

+1(312) 503-5978


Department of Neurological Surgery, Lurie Comprehensive Cancer Center


SQ 6-521, 303 E. Superior St.



Areas of Research

Cell Biology, Mechanisms of Drug Action, Neurobiology of Disease, Signal Transduction

NU Scholar Profile


Recent Publications on PubMed


Current Research

Current Research

The goal of my laboratory is to develop novel approaches to prevent therapeutic resistance and disease recurrence in glioblastoma, one of most lethal cancers in humans. We are interested in understanding the mechanisms of therapeutic resistance and identify actionable target(s) to prevent recurrence. The recent understanding of the cellular adaptation process proposed that epigenetic regulators work in concert with the cellular plasticity to promote therapeutic resistance. In my lab, we are currently utilizing state of the art technologies such as single cell transcriptomic and epigenetic analysis to elucidate the mechanisms of resistance to develop novel anti-glioma therapy.

Selected Publications

Selected Publications

1. Baisiwala S, Auffinger B, Caragher SP, Shireman JM, Ahsan R, Lee G, Hasan T, Park C, Sathoff MR, Christensen AC, Ahmed AU*. Chemotherapeutic stress induces transdifferentiation of glioblastoma cells to endothelial cells and promotes vascular mimicry. Stem Cells International. 2019; 2019: 1-14.
2. Miska J, Lee-Chang C, Rashidi A, Muroski ME, Chang AL, Lopez-Rosas A, Zhang P, Panek WK, Cordero A, Han Y, Ahmed AU, Chandel NS, Lesniak MS. HIF-1alpha Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma. Cell Rep. 2019; 27(1): 226-37 e4. PMID: 30943404; PMCID: PMCPMC6461402;
3. Hasan T, Caragher SP, Shireman JM, Park CH, Atashi F, Baisiwala S, Lee G, Guo D, Wang JY, Dey M, Wu M, Lesniak MS, Horbinski CM, James CD, Ahmed AU*. Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma. Cell Death Dis. 2019; 10(4): 292. PMID: 30926789; PMCID: PMCPMC6441047;
4. Caragher SP, Shireman JM, Huang M, Miska J, Atashi F, Baisiwala S, Hong Park C, Saathoff MR, Warnke L, Xiao T, Lesniak MS, James CD, Meltzer H, Tryba AK, Ahmed AU*. Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma. J Neurosci. 2019; 39(11): 1982-93. PMID: 30651332; PMCID: PMCPMC6507082;
5. Yu D, Khan OF, Suva ML, Dong B, Panek WK, Xiao T, Wu M, Han Y, Ahmed AU, Balyasnikova IV, Zhang HF, Sun C, Langer R, Anderson DG, Lesniak MS. Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proc Natl Acad Sci U S A. 2017; 114(30): E6147-E56. PMID: 28696296; PMCID: PMCPMC5544292;
6. Lee G, Auffinger B, Guo D, Hasan T, Deheeger M, Tobias AL, Kim JY, Atashi F, Zhang L, Lesniak MS, James CD, Ahmed AU*. Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model. Mol Cancer Ther. 2016; 15(12): 3064-76. PMID: 27765847; PMCID: PMCPMC5298928;
7. Kanojia D, Morshed RA, Zhang L, Miska JM, Qiao J, Kim JW, Pytel P, Balyasnikova IV, Lesniak MS, Ahmed AU. betaIII-Tubulin Regulates Breast Cancer Metastases to the Brain. Mol Cancer Ther. 2015; 14(5): 1152-61. PMID: 25724666; PMCID: PMCPMC4425587;
8. Alexiades NG, Auffinger B, Kim CK, Hasan T, Lee G, Deheeger M, Tobias AL, Kim J, Balyasnikova I, Lesniak MS, Aboody K, Ahmed AU*. MMP14 as a novel downstream target of VEGFR2 in migratory glioma-tropic neural stem cells. Stem Cell Res. 2015; 15(3): 598-607. PMID: 26513555; PMCID: PMCPMC4698038;